Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Thursday.
A number of other analysts have also issued reports on ABEO. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.
Get Our Latest Stock Report on Abeona Therapeutics
Abeona Therapeutics Stock Down 1.7 %
Shares of NASDAQ ABEO traded down $0.10 during midday trading on Thursday, reaching $5.91. 158,268 shares of the company's stock were exchanged, compared to its average volume of 420,344. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The business's fifty day moving average price is $6.25 and its two-hundred day moving average price is $5.45. The stock has a market capitalization of $256.91 million, a PE ratio of -2.20 and a beta of 1.44.
Institutional Investors Weigh In On Abeona Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics in the 3rd quarter worth about $84,000. Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics in the 3rd quarter worth about $151,000. XTX Topco Ltd acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at approximately $160,000. GSA Capital Partners LLP raised its holdings in shares of Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company's stock valued at $607,000 after buying an additional 33,831 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock worth $515,000 after buying an additional 2,434 shares during the period. 80.56% of the stock is currently owned by institutional investors.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
